BLR Bio Receives Orphan Drug Designation

The U.S. Food and Drug Administration (FDA) granted an Orphan Drug Designation for an investigational therapy under development by Helix 51 company BLR Bio for the treatment of scleroderma, a rare rheumatic disease that affects connective tissue and the vascular system. “The FDA’s granting of Orphan Drug Designation to BLR-200 highlights the urgent need for new and innovative therapeutic options for patients afflicted with the disease,” said Bruce Riser, PhD, CEO of BLR Bio.

Click here to learn more.